Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus
…, L Colloca, E Torre, M Lanotte, A Melcarne… - Nature …, 2004 - nature.com
Placebo administration is known to affect the brain both in pain and in Parkinson disease.
Here we show that placebo treatment caused reduced activity in single neurons in the …
Here we show that placebo treatment caused reduced activity in single neurons in the …
The genetic and metabolic signature of oncocytic transformation implicates HIF1α destabilization
…, I Morra, E Ciccarelli, A Melcarne… - Human molecular …, 2010 - academic.oup.com
We previously showed that disruptive complex I mutations in mitochondrial DNA are the
main genetic hallmark of oncocytic tumors of the thyroid and kidney. We here report a high …
main genetic hallmark of oncocytic tumors of the thyroid and kidney. We here report a high …
Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies
…, L Gennero, MA Roos, A Melcarne… - Cell biochemistry …, 2010 - Wiley Online Library
Glioblastoma Multiforme (GBM) is an incurable malignancy. GBM patients have a short life
expectancy despite aggressive therapeutic approaches based on surgical resection followed …
expectancy despite aggressive therapeutic approaches based on surgical resection followed …
WNT/β-catenin signaling pathway and downstream modulators in low-and high-grade glioma
…, L Annovazzi, P Cassoni, A Melcarne… - Cancer genomics & …, 2016 - cgp.iiarjournals.org
Background: Aberrant activation of the canonical Wingless-type MMTV integration site family
(WNT)/β-catenin signaling pathway is critical for gliomas. Materials and Methods: In 74 …
(WNT)/β-catenin signaling pathway is critical for gliomas. Materials and Methods: In 74 …
Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation
…, B Bono, L Giordano, P Zeppa, A Melcarne… - Clinical Cancer …, 2023 - AACR
Purpose: Current glioma diagnostic guidelines call for molecular profiling to stratify patients
into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, …
into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, …
[HTML][HTML] The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment
…, L Battaglia, D Chirio, A Melcarne… - International …, 2015 - spandidos-publications.com
Therapeutic resistance in glioblastoma multiforme (GBM) has been linked to a subpopulation
of cells with stem cell-like properties, the glioma stem cells (GSCs), responsible for cancer …
of cells with stem cell-like properties, the glioma stem cells (GSCs), responsible for cancer …
[HTML][HTML] Management of extramedullary intradural spinal tumors: the impact of clinical status, intraoperative neurophysiological monitoring and surgical approach on …
…, G Di Perna, CV Junemann, A Melcarne… - Frontiers in …, 2020 - frontiersin.org
Objective: Intradural Extramedullary (IDEM) tumors are usually treated with surgical excision.
The aim of this study was to investigate the impact on clinical outcomes of pre-surgical …
The aim of this study was to investigate the impact on clinical outcomes of pre-surgical …
[HTML][HTML] Stem cell niches in glioblastoma: a neuropathological view
…, A Piazzi, T Denysenko, A Melcarne - BioMed research …, 2014 - hindawi.com
Glioblastoma (GBM) stem cells (GSCs), responsible for tumor growth, recurrence, and
resistance to therapies, are considered the real therapeutic target, if they had no molecular …
resistance to therapies, are considered the real therapeutic target, if they had no molecular …
Fluorescence-guided surgery for high-grade gliomas: state of the art and new perspectives
…, P Zeppa, GD Perna, A Melcarne… - … in Cancer Research …, 2021 - journals.sagepub.com
High-grade gliomas are aggressive tumors that require multimodal management and gross
total resection is considered to be the first crucial step of treatment. Because of their …
total resection is considered to be the first crucial step of treatment. Because of their …
[HTML][HTML] Updates in glioblastoma immunotherapy: an overview of the current clinical and translational scenario
…, G Aruta, M Monticelli, P Zeppa, F Tartara, A Melcarne… - Biomedicines, 2023 - mdpi.com
Glioblastoma (GBM) is the most common and aggressive central nervous system tumor,
requiring multimodal management. Due to its malignant behavior and infiltrative growth pattern, …
requiring multimodal management. Due to its malignant behavior and infiltrative growth pattern, …